Abstract
recentlypublishedinyourjournal.Inthepaper,theauthorsclaimedthat there was an increase of clonal gammopathiesfollowing alemtuzumab-based reduced-intensity condition-ing hematopoietic stem cell transplantation. The authorsconcludethattherewasnodifferenceinthenumberofviralinfections (that is, CMV and HBV) in patients developingclonal gammopathies. The majorcausative role forthedevelopment of clonal gammopathies after organ trans-plantation is thought to be EBV as supported by severalreports in the literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
